divided by 12. (c) Highly rebated drug previously subject to formulary exclusion Beginning on January 1, 2025, in the case of a specific highly rebated drug covered by a group health plan or health insurance issuer offering group or individual health insurance coverage (or entity that provides pharmacy benefits management services on behalf of such plan or issuer) that provides coverage of a specific highly rebated drug that was not covered in the previous year, such group health plan or health insurance issuer shall not receive from a drug manufacturer a reduction in price or other remuneration with respect to such specific highly rebated drug received by an enrollee in the plan or coverage and covered by the plan or coverage, unless— (1) any such reduction in price is reflected at the point of sale to the enrollee